National Bank of Canada FI bought a new stake in shares of Incyte Co. (NASDAQ:INCY – Get Rating) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 595 shares of the biopharmaceutical company’s stock, valued at approximately $44,000.
Several other institutional investors have also made changes to their positions in the company. IndexIQ Advisors LLC lifted its stake in shares of Incyte by 5.1% in the 3rd quarter. IndexIQ Advisors LLC now owns 3,222 shares of the biopharmaceutical company’s stock valued at $222,000 after purchasing an additional 157 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich increased its holdings in shares of Incyte by 6.0% in the 3rd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 2,823 shares of the biopharmaceutical company’s stock valued at $194,000 after acquiring an additional 160 shares during the period. Ieq Capital LLC raised its holdings in Incyte by 5.1% in the third quarter. Ieq Capital LLC now owns 3,394 shares of the biopharmaceutical company’s stock worth $234,000 after purchasing an additional 165 shares in the last quarter. Mutual of America Capital Management LLC raised its stake in shares of Incyte by 0.9% during the 3rd quarter. Mutual of America Capital Management LLC now owns 27,473 shares of the biopharmaceutical company’s stock worth $1,890,000 after acquiring an additional 250 shares in the last quarter. Finally, Vident Investment Advisory LLC lifted its holdings in shares of Incyte by 4.5% during the 3rd quarter. Vident Investment Advisory LLC now owns 5,994 shares of the biopharmaceutical company’s stock valued at $412,000 after purchasing an additional 260 shares during the last quarter. Institutional investors and hedge funds own 91.33% of the company’s stock.
In related news, EVP Jonathan Elliott Dickinson sold 7,375 shares of the company’s stock in a transaction that occurred on Monday, January 31st. The shares were sold at an average price of $74.19, for a total value of $547,151.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bros. Advisors Lp Baker bought 292,972 shares of the stock in a transaction on Thursday, February 17th. The shares were acquired at an average cost of $67.74 per share, for a total transaction of $19,845,923.28. The disclosure for this purchase can be found here. In the last three months, insiders purchased 711,335 shares of company stock worth $49,689,821. Company insiders own 15.80% of the company’s stock.
Incyte (NASDAQ:INCY – Get Rating) last released its quarterly earnings results on Tuesday, February 8th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.65 by ($0.72). Incyte had a net margin of 31.76% and a return on equity of 14.66%. The firm had revenue of $862.50 million for the quarter, compared to analyst estimates of $813.38 million. During the same period in the previous year, the business posted $0.73 earnings per share. Incyte’s revenue for the quarter was up 9.4% on a year-over-year basis. Equities analysts forecast that Incyte Co. will post 2.52 EPS for the current fiscal year.
A number of equities research analysts recently commented on INCY shares. JMP Securities reiterated a “buy” rating and issued a $108.00 target price on shares of Incyte in a research report on Friday, December 17th. StockNews.com started coverage on shares of Incyte in a research report on Thursday, March 31st. They issued a “strong-buy” rating on the stock. Morgan Stanley lowered their price target on Incyte from $77.00 to $76.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 2nd. Royal Bank of Canada raised shares of Incyte from a “sector perform” rating to an “outperform” rating and upped their price objective for the company from $78.00 to $90.00 in a research note on Tuesday, January 18th. Finally, Guggenheim cut their target price on Incyte from $118.00 to $104.00 in a research note on Monday, January 3rd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $87.82.
About Incyte (Get Rating)
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib).
- Get a free copy of the StockNews.com research report on Incyte (INCY)
- Conagra Stock Has More Room to Grow
- 3 Recession-Proof Stocks to Buy Now
- MarketBeat: Week in Review 4/4 – 4/8
- 3 Best Life Sciences Stocks to Buy Now
- The Institutional Insiders Are Buying WD-40 Company
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.